Treatment of chronic wounds by local delivery of granulocyte-macrophage colony-stimulating factor in patients with neutrophil dysfunction.
Chronic wounds are associated with considerable morbidity and prolonged hospitalizations. The availability of recombinant growth factors and cytokines provides a new modality for treatment of recalcitrant wounds. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a growth protein for hematopietic cells, also enhances neutrophil and monocyte function and promotes keratinocyte proliferation. In three patients with inherited disorders associated with leukocyte dysfunction and non-healing wounds, topical application of GM-CSF resulted in complete wound closure within 1 to 4 weeks. A subcutaneous (s.c.) infusion pump for the local s.c. delivery of GM-CSF was also found to enhance healing. Local application of GM-CSF may thus promote wound closure in patients with impaired wound healing.
De Ugarte
Daniel A
DA
Division of Pediatric Surgery, UCLA School of Medicine, 90095, USA.
Roberts
Robert L
RL
Lerdluedeeporn
Paisal
P
Stiehm
E Richard
ER
Atkinson
James B
JB
D000287:Administration, Topical; D000293:Adolescent; D002675:Child, Preschool; D016503:Drug Delivery Systems; D005260:Female; D005953:Glycogen Storage Disease Type I / Q000188:drug therapy* / Q000503:physiopathology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006105:Granulomatous Disease, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D036502:Infusions, Intralesional; D008297:Male; D009504:Neutrophils / Q000502:physiology; D011994:Recombinant Proteins; D014945:Wound Healing / Q000187:drug effects*
D011994:Recombinant Proteins; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor